XML 75 R55.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Note 10 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($) |  | 1 Months Ended | 12 Months Ended | 40 Months Ended | 50 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jun. 16, 2015 | Sep. 30, 2013 | Feb. 24, 2011 | May 31, 2010 | Sep. 30, 2009 | Jan. 31, 2007 | Jun. 30, 2006 | Feb. 28, 2006 | Jun. 30, 2000 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2016 | Feb. 24, 2011 | Mar. 31, 2015 | Nov. 11, 2011
CSL Limited [Member |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from License Fees Received | $ 33,740,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment Maximum | $ 12,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Base Contract [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Government Contract Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 16,265,000 |
Additional Development Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Government Contract Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,855,000 |
ASPRBARDA Contract [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Government Contract Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 39,120,000 |
Proceeds from awards for Research and Development Contracts |  |  |  |  |  |  |  |  |  | $ 20,574,000 |  |  |  |  |
Green Cross Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from License Fees Received |  |  |  |  |  |  | $ 250,000 |  |  |  |  |  |  |  |
Mundipharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront Payments Receivable Amount |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |
Potential Milestone Payments Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000
Mundipharma [Member] | Upfront Payment [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |
AECOM and IRL [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment Maximum |  |  |  |  |  |  |  |  | $ 4,000,000 |  |  |  |  |  |
Milestone Payment Minimum |  |  |  |  |  |  |  |  | 1,400,000 |  |  |  |  |  |
Annual License Fee Minimum |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |
Annual License Fee Maximum |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |
Advance Notice Period for Termination of Agreement |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |
Stock Issued During Period, Value, for Modification of License Agreement |  |  |  | $ 5,911,000 |  |  |  |  |  |  |  |  |  |  |
Payments for Modification of License Agreement |  |  |  | $ 90,000 |  |  |  |  |  |  |  |  |  |  |
US Department of Health and Human Services [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreement Contract Value |  |  |  |  |  | $ 102,661,000 |  |  |  |  |  |  |  |  |
Collaborative Agreement Additional Contract Value |  |  | $ 55,000,000 |  | $ 77,191,000 |  |  |  |  |  |  |  |  |  |
Collaborative Agreement Adjusted Contract Value |  |  |  |  |  |  |  |  |  |  |  |  | $ 234,852,000 |  |
National Institute of Allergy and Infectious Diseases [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from awards for Research and Development Contracts |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Expected Receivable From Awards for Research and Development Contracts |  |  |  |  |  |  |  |  |  |  |  | $ 39,477 |  |  |
UAB [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of Agreement |  |  |  |  |  |  |  |  |  |  | 25 years |  |  |  |

X
- Definition Represents advance notice period for termination of agreement. + References No definition available. + Details
Name: | bcrx_AdvanceNoticePeriodForTerminationOfAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents annual maximum license fee. + References No definition available. + Details
Name: | bcrx_AnnualLicenseFeeMaximum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represent minimum annual license fee. + References No definition available. + Details
Name: | bcrx_AnnualLicenseFeeMinimum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative agreement additional contract value during the period. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementAdditionalContractValue
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents collaborative agreement adjusted contract value. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementAdjustedContractValue
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents collaborative agreement contract value. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractValue
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents expected receivable from awards for research and development contracts. + References No definition available. + Details
Name: | bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents milestone payment maximum. + References No definition available. + Details
Name: | bcrx_MilestonePaymentMaximum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents milestone payment minimum. + References No definition available. + Details
Name: | bcrx_MilestonePaymentMinimum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents payments for modifications of license agreement. + References No definition available. + Details
Name: | bcrx_PaymentsForModificationOfLicenseAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents period of agreement. + References No definition available. + Details
Name: | bcrx_PeriodOfAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents potential milestone payments receivable based on possibility of future event payments. + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivable
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents proceeds from awards for research and development contracts. + References No definition available. + Details
Name: | bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents stock issued during period value for modification of license agreement. + References No definition available. + Details
Name: | bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents upfront payments receivable. + References No definition available. + Details
Name: | bcrx_UpfrontPaymentsReceivableAmount
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of receivables that are derived from government contracts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68054760&loc=d3e55295-109406 + Details
Name: | us-gaap_GovernmentContractReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |